Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
0.423
-0.992 (-70.11%)
Apr 28, 2026, 2:47 PM EDT - Market open
Soligenix Employees
As of December 31, 2025, Soligenix had 14 total employees, including 13 full-time and 1 part-time employees. The number of employees decreased by 2 or -12.50% compared to the previous year.
Employees
14
Change (1Y)
-2
Growth (1Y)
-12.50%
Revenue / Employee
n/a
Profits / Employee
-$791,456
Market Cap
4.36M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| BioCardia | 21 |
| IN8bio | 17 |
| Moleculin Biotech | 17 |
| SeaStar Medical Holding | 17 |
| Intensity Therapeutics | 7 |
| Phio Pharmaceuticals | 6 |
| CDT Equity | 6 |
| Jupiter Neurosciences | 5 |
SNGX News
- 7 hours ago - Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire
- 26 days ago - Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy - PRNewsWire
- 4 weeks ago - Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results - PRNewsWire
- 4 weeks ago - Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease - PRNewsWire
- 5 weeks ago - HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 - PRNewsWire
- 5 weeks ago - IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc. - GlobeNewsWire
- 5 weeks ago - Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs" - PRNewsWire
- 7 weeks ago - Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency - PRNewsWire